---
search:
  boost: 3
---

# NSAIDs

This is a subcategory of Ophthalmic Agents.

## Decision Tree

- [Ophthalmic - NSAIDS - Non-Preferred Criteria - Acuvail, Bromfenac, Bromsite, Ilevro, Nevanac, Prolensa](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQVZUMTlJVllURFZNNFZVWkhUVjhJOTdHMiQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred    | Generic Name | Quantity | Time (Days) |
|:-------------|:-------------|:--------:|:-----------:|
| Diclofenac   |              |          |             |
| Flurbiprofen |              |          |             |
| Ketorolac    |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
|:--------------|:-------------|:--------:|:-----------:|
| Acuvail       |              |          |             |
| Bromfenac     |              |          |             |
| Bromsite      |              |          |             |
| Ilevro        |              |          |             |
| Nevanac       |              |          |             |
| Prolensa      |              |          |             |

## Authorizations

**Length of Authorizations**: 30 days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria 

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **3 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7B73347C85-1D40-4514-80E9-9628185B51B4%7D&file=Denial%20Language%20Updated%2001012024.docx&action=embedview&mobiledirect=true&wdStartOn=88){:target="_blank" rel="noopener"}

[Criteria](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#page=93){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20effective%2001.01.2024.pdf#page=30){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
